trial
as of 2026-07-01Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
NCTId NCT03495024
at a glance
Phase 4 · Recruiting
Enrollment 10 (estimated)
Sponsored by Corporal Michael J. Crescenz VA Medical Center
Primary completion 2020-04-30
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Recruiting
Enrollment
10 (estimated)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-01-01
Primary completion
2020-04-30
Eligibility
ALL · 18 Years · 75 Years
Interventions & indications
Sponsors
Corporal Michael J. Crescenz VA Medical CenterLead Sponsor
Investigators
1
Stanley N Caroff, MDPrincipal Investigator
Sites
1 total
Philadelphia, United States
Facts & assertions
4 sourced
Enrollment
10
Phase
PHASE4
Primary Completion Date
2020-04-30
Status
RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person